Newsroom
Establishment and inaugural meeting of the Clinical and Scientific Advisory Board
Synapse Electroceutical Limited are delighted to announce the establishment of a Clinical and Scientific Advisory Board comprised of eminent experts in the fields of Wound Healing research, science, clinical practice, pain management and health economics.
Read this articleSynapse CEO announcement
Synapse Electroceutical today announced that the Board of Directors has appointed Andy Boyes as Interim Chief Executive Officer. John Gildersleeve will assume the role of Business Development Director and will continue to serve as an executive director on the Board.
Read this article
Andy Boyes appointed as Non-Executive Director to Synapse Electroceutical Limited
Synapse Electroceutical Limited is delighted to announce the appointment of Andy Boyes to the Board. Andy has enjoyed a successful, 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of £4 billion. Andy is passionate
about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focussed on providing Board level support and strategic direction in the sector.
Other articles
- 'Electrical stimulation therapy and electroceutical treatment for the management of venous leg ulcers’ published in Community Wound Care
- ‘The health economic burden that acute and chronic wounds impose on an average clinical commissioning group / health board in the UK’ published in the Journal of Wound Care
- ‘Health economic burden that different wound types impose on the UK’s National Health Service’ published in the International Wound Journal
- 'Using electroceutical treatment to reduce symptoms and improve healing in chronic wounds’ published in Primary Health Care
- 'Breaking the cycle of hard-to-heal wounds with electroceutical treatment’ presentation to the Leg Ulcers: Right Care, Right Time Wounds UK Nurse Symposium
- 'Venous leg ulcer management in clinical practice in the UK: costs and outcomes’ published in the International Wound Journal
- 'Right Care, Right Time - An evaluation using an electroceutical treatment to determine the clinical outcomes in a large NHS Trust’ poster presented at Wounds UK
- Synapse Electroceutical Limited supports Bromley Healthcare Charity
- TVNI Meeting 2017
- Best Practice Event 2016
- Accel‑Heal® on BBC News
- Accel‑Heal® offers a potential saving of £495 million to the NHS
- Japanese Patent and Australia and New Zealand Trademarks for Accel‑Heal®
- Living with a leg ulcer
Regulatory and IP
All Synapse electroceutical products are designed and manufactured to conform with the highest standards of quality and safety.
All our products adhere to the quality standards dictated by the International Organisation for Standardization (ISO), Medical Device Directive (MDD), Medical Device Classification and carry the Conformité Européenne (CE) marking. In 2007 Synapse Micro-Current Ltd achieved ISO 9001 Quality Management Systems and ISO 13485 accreditation for the design and manufacture of medical devices for sport and medical applications. In addition, Synapse has over 50 patents already granted and several pending in key territories of the world as well as a number of registered trademarks.
Synapse Electroceutical medical products are officially certified as Class IIA devices under the medical device directive 93/42/EEC.
Accel-Heal® carries the CE mark having been tested and approved by Notified Body 0120 Accel-Heal® is manufactured to ISO 13485:2016 for the design and manufacture of medical devices.
- Click here to download a (pdf) copy of the ISO 13485 certification
- Click here to download a (pdf) copy of the ISO 93/42 EEC certification
- Click to download a (pdf) copy of the declaration of conformity
All Synapse Electroceutical products carry the CE marking.
For a comprehensive document covering hazards, contra-indications and warranty please visit this link.
The Synapse Electroceutical Accel-heal® unit is classified as Class IIA medical devices, having been tested and approved by Notified Body 0120 at meeting the standards of the Medical Devices Directive and the ISO 13485 management system.
Therapeutic Goods Administration (TGA) Approval for Accel-Heal in Australia.
You can view our news stories by category
